Proteomic and Metabolomic Investigation of COVID-19 Patients with Elevated Serum Lactate Dehydrogenase

Haixi Yan[1#], Xiao Liang[2,3,4#], Juping Du[1,#], Zebao He [1,#], Yu Wang[5], Mengge Lyu[2,3,4], Liang Yue[2,3,4], Fangfei Zhang [2,3,4], Zhangzhi Xue[2,3,4], Luang Xu[2,3,4], Guan Ruan[6], Jun Li[1], Hongguo Zhu [1], Jiaqin Xu [1], Shiyong Chen[1], Chao Zhang[1], Dongqing Lv[1], Zongmei Lin[1], Bo Shen[1], Yi Zhu[2,3,4†], Biyun Qian[5,†], Haixiao Chen[1,†], Tiannan Guo[2,3,4†]

[1] Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, 150 Ximen Street, Linhai 317000, Zhejiang Province, China

[2] Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China

[3] Center for Infectious Disease Research, Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou 310024, China

[4] Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, 18 Shilongshan Road, Hangzhou 310024, Zhejiang Province, China

[5] Hongqiao International Institute of Medicine, Shanghai Tongren Hospital and Faculty of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

[6] Westlake Omics (Hangzhou) Biotechnology Co., Ltd. No.1, Yunmeng Road, Cloud Town, Xihu District, Hangzhou, Zhejiang Province, China

[#] These authors contributed equally to this study.

[†] Correspondence and requests for materials should be addressed to Z.Y. (zhuyi@westlake.edu.cn), B.Q. (qianbiyun@sjtu.edu.cn), H.C. (chenhx@enzemed.com), and T.G. (guotiannan@westlake.edu.cn).

Keywords: COVID-19; lactate dehydrogenase; proteomics; metabolomics; biomarker; prognosis

Abstract

   Serum lactate dehydrogenase (LDH) has been established as a prognostic indicator given its differential expression in COVID-19 patients. However, the molecular mechanisms underneath remain poorly understood. In this study, 144 COVID-19 patients were enrolled to monitor the clinical and laboratory parameters over three weeks. Serum lactate dehydrogenase (LDH) was shown elevated in the COVID-19 patients on admission and declined during the convalescence period, and its ability to classify patient severity outperformed other clinical indicators. A threshold of 247 U/L serum LDH on admission was determined for severity prognosis. Next, we classified a subset of 14 patients into high- and low-risk groups based on serum LDH expression and compared their quantitative serum proteomic and metabolomic differences. The results found COVID-19 patients with high serum LDH exhibited differentially expressed blood coagulation and immune responses including acute inflammatory responses, platelet degranulation, complement cascade, as well as multiple different metabolic responses including lipid metabolism, protein ubiquitination and pyruvate fermentation. Specifically, activation of hypoxia responses was highlighted in patients with high LDH expressions. Taken together, our data showed that serum LDH levels is associated COVID-19 severity, and that elevated serum LDH might be consequences of hypoxia and tissue injuries induced by inflammation.

INTRODUCTION

COVID-19 is an ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A high viral transmission rate and the lack of effective therapy contributed to more than 83 million infected cases as of time January 3rd, 2021 [1].

To better diagnose COVID-19 and monitor the disease progress, multiple molecules have been proposed as prognostic indicators [2]. Lactate dehydrogenase (LDH) is an intracellular enzyme, catalyzing pyruvate fermentation and facilitating glycolysis. LDH is released into the blood after cell death and has been reported to increase in a variety of diseases including Severe acute respiratory syndrome (SARS) [3], diabetes [4], and cancers [5]. Serum LDH levels in COVID-19 patients are over-expressed [2], especially in severe and critical patients [6-9]. They decrease during convalesce stage [7, 10], in correlation with viral mRNA clearance [7]. Related studies have shown that serum LDH is well correlated with respiratory failure [11], lung injury, disease severity [12] and mortality [13] in COVID-19 patients.

However, the molecular mechanisms underlying the LDH's association with the COVID-19 disease progression remains poorly understood. Most studies attribute serum LDH elevation to its release from somatic tissue and organ damage caused by either viral attack [12] or inflammation [10]. These clinical assumptions lack molecular evidence, potentially leading to biased assessments. Moreover, these explanations failed to consider the metabolic role of LDH to balance excess lactate during hypoxia. Here we systematically explored the proteome and metabolome of sera from COVID-19 patients with low and high serum LDH, and identified the specific host responses, which shed light on the pathogenesis and convalesce of COVID-19.

MATERIALS AND METHODS

Patient Information

We collected and curated the electronic medical records of patient information in Taizhou Hospital of Zhejiang Province, between January 17 and February 20, 2020. 212 patients met the criteria of suspected COVID-19, of which 145 patients were confirmed as COVID-19, based on the Government's Diagnosis and Treatment Guideline (5th version) [14]. 144 patients COVID-19 patients were included in this study after excluding one patient who had incomplete laboratory data. According to the admission period, we grouped them into two cohorts. Patients admitted to Taizhou Public Health Medical Center, Taizhou Hospital between January 17 and February 4, 2020 were included in the cohort 1 (n = 115). The cohort 2 (n = 29) contained COVID-19 patients admitted from February 4 to February 20, 2020. The end of the follow-up date was March 1, 2020. Patients were clinically determined as mild, typical and severe according to the abovementioned guideline, and the former two types were both described as non-severe. This study is approved by the institutional medical ethics review board of Taizhou Hospital of Zhejiang Province and Westlake University.

Laboratory tests

For laboratory tests, blood samples from 144 patients were centrifuged at 1500 g for 10 min at room temperature. The supernatant was collected to obtain serum. Seven biochemical indicators were tested, namely lactate dehydrogenase (LDH), aspartate

99   aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, total protein,
100   creatinine, and creatine kinase (CK), with a Chemistry Analyzer (Beckman Coulter,
101   AU5821).
102
Proteomic and metabolomic data set
The proteomic and metabolomic data were extracted from our previous publication
[15]. Briefly, for proteomic experiments, inactivated serum samples were processed
into peptides, labeled with TMTpro 16plex chemical tags, fractionated to 40 aliquots,
and analyzed by LC-MS/MS. The proteomics data were analyzed with Proteome
Discoverer (Version 2.4.1.15, Thermo Fisher Scientific). 894 proteins were quantified
altogether. For metabolomic experiments, inactivated serum samples were processed
to collect metabolites, and divided into 4 fractions for 4 different modes of
LC-MS/MS data acquisition, leading to characterization of 941 metabolites.
112
Statistical analysis
Statistical clinical data analyses were performed using SPSS software (version
22.0). Continuous variables were presented as median and interquartile range (IQR)
values, while categorical variables were shown as frequency and percentage. An
independent t-test was used for continuous variables when the data were normally
distributed; otherwise, the Mann-Whitney test was used. Chi-square test or Fisher's
exact test was used for categorical variables. Receiver operating characteristic (ROC)
analysis was used for the selection of the best intercept point. Prediction of disease
progression was obtained using the Cox proportional hazards model. Statistical
proteomic data analysis was performed using R (version 3.6.1). Missing values in the
proteomic data matrix were assigned as 0.01 unless otherwise mentioned. P values $\leq$
0.05 were considered statistically significant unless otherwise mentioned. Differential
protein expression was based on the cutoff: P values ≤ 0.05, $|\log_2 FC| > 0.25$. Plotting
was performed with R (version 3.6.1).
127
RESULTS AND DISCUSSION
Demographic, clinical, and laboratory characteristics
A total of 144 COVID-19 patients were enrolled in the study. Detailed demographic,
clinical, and laboratory characteristics of these patients on admission were provided in
Table 1. The median age was 47 years old, and 53.5% of them were male. The severe
patients account for 25% (36/144) of the group, were 10 years older than the
non-severe patients (55 vs. 45, $p < 0.001$), and were more likely to have fever
symptoms on admission ($p = 0.002$). Severe patients received more treatment of
oxygen inhalation ($p < 0.001$), antibiotics ($p = 0.024$), glucocorticoid ($p < 0.001$), and
intravenous gamma immunoglobulin ($p < 0.001$). The patients did not exhibit
significant difference between severe and non-severe groups in terms of gender
unmentioned symptoms on admission, nor other medical treatments ($p > 0.05$) as
listed in Table 1.
Based on laboratory test results, a higher percentage of severe patients have
elevated levels of serum LDH that are above the upper limit of normal (ULN) value
than non-severe patients (58.3% vs. 8.3%, $p < 0.001$). Likewise, more severe patients
also showed higher level of alanine aminotransferase (ALT, $p = 0.041$), aspartate
aminotransferase (AST, $p < 0.001$), urea ($p = 0.004$), creatinine ($p = 0.014$), and
creatine kinase (CK, $p < 0.001$). We then compared their temporal changes at 7-day

intervals (Supplementary Table 1). LDH, CK, and creatinine showed continuous
decrease in the sera of severe patients, while only serum LDH showed a continuous
decrease in non-severe patients.
A Cox regression model was applied to evaluate the prognostic value of these
indicators (Supplementary Table 2). In the Cohort 1, LDH, AST, and CK were
determined in the univariate analysis as indicators with the best discrimination ($p <$
0.001), while LDH was further determined in the multivariate analysis with the best
discrimination ($p < 0.001$). We further validated the value of serum LDH in Cohort 2
and the data showed significant discrimination ($p = 0.037$), suggesting that serum
LDH could be a useful prognostic biomarker.
157
Temporal characteristics of Serum LDH in COVID-19 patients
We then checked the effect of age and sex on the temporal serum LDH expression.
Patients older than 60 years showed a higher serum LDH expression throughout the
disease course than younger patients (Figure 1A). Males expressed higher serum LDH
levels than that from females during the initial hospitalization stage (<10 days), while
afterwards the serum LDH became comparable between genders (Figure 1B).
We compared the median values of serum LDH levels from the initial admission
stage (1-3 days after admission) and discharge stage (1-3 days before discharge), in a
sub-cohort of recovered patients that were discharged by the end of follow-up. (total:
n=49; severe: n=13; non-severe: n=36) (Figure 1C). Serum LDH levels were
significantly higher in the severe patient group, particularly on admission ($p < 0.01$).
To better understand the temporal dynamics of serum LDH expression over the
disease course, we next monitored the serum LDH level from day 1 on admission till
day 21 at a 3-day interval (Figure 1D). As to the non-severe patient group, the serum
LDH level was slightly higher on admission while declining slowly over the
hospitalization period. The serum LDH levels in the severe group comparatively were
significantly higher upon admission, with a prominent variance range. They dropped
significantly from 3rd to 9th day as the patients were taking medical care and by the
21st day fell below the initial serum LDH levels in the non-severe group.
177
Classification of low- and high-risk patients based on serum LDH levels
To establish a cohort-specific serum LDH expression threshold as a risk indicator,
we took patient severity (severe vs. non-severe) as the dichotomous variable and
conducted the receiver operating characteristic (ROC) analysis on the serum LDH
expression levels on admission. The area under curve (AUC) was 0.855 (Figure 1E),
confirming the discriminative power of serum LDH. The serum LDH level
corresponding to the maximum Youden index was determined as 247 U/L, equivalent
to the threshold from past reports (245-253.2 U/L) [13].
Fourteen characteristic patients within the cohort were selected and divided into
two groups for closer inspection (Figure 1H). The low-risk (LR) group consists of
seven non-severe patients with serum LDH expressions below 247 U/L since
admission except for one exceptional detection (LR4, 5th day, 306 U/L). The high-risk
(HR) group are composed of six severe patients with on admission serum LDH levels
above 247 U/L, and one severe patient with serum LDH levels below the threshold
throughout hospitalization (HR1). We attribute this to the relatively late first sampling
timepoint (8th day), given that serum LDH levels from all the patients started at a
relatively high level and declined over time. Patient HR3 and patient HR7 in
particular had exceptionally high serum LDH levels (> 450 U/L) upon admission but

dropped dramatically within 10 days. We inspected the detailed medical records of the 14 patients (Table 2). COVID-19 patients with comorbidities including hypertension, chronic HBV infection, and diabetes tend to be severe patients in the HR group, in consistent with the literature [16, 17].

Quantitative proteomics and metabolomics uncover dysregulated molecules associated with elevated serum LDH

The serum proteomic and metabolomic datasets of the HR and LR group patients were extracted from a collateral project [15]. 78.6% (11/14) of the patient sera were sampled during the first week on admission (Table 2), herein representing the stage when serum LDH levels exhibited sharp difference between the LR and HR groups. For the proteomic dataset, the Student's *t*-test highlighted 34 proteins as differentially expressed ($p < 0.05$) between HR and LR groups (Figure 2A, upper panel), 26 of which were up-regulated. Pathway enrichment analysis using Metascape [18] showed these proteins conduct three major immune-related activities including acute inflammatory responses (GO:0002526, $p < 0.001$), platelet degranulation (GO:0002576, $p < 0.001$) and regulation of complement cascade (R-HSA-977606, $p < 0.001$) (Figure 2A and Supplementary Fig. 1A). Additional analyses using Ingenuity Pathway Analysis (IPA) nominated acute phase response signaling as the most activated immune-related pathway (Supplementary Fig. 1C) in HR patients. These findings were in consistence with the prominent immune behaviors (Supplementary Fig. 1B) as we have previously reported in COVID-19 patients with different severity [15]. Moreover, blood coagulation (GO: 007596, $p < 0.001$) was significantly enriched (Supplementary Fig. 1A and 1C). This pathway has been reported to be altered in COVID-19, and associated with interleukin-6 (IL-6))[19]. Our data showed upregulation of acute phase proteins (SAA1, ORM1, AGT, and SERPINA3), complement subunits (C9, C6, and CFI), and LDH subtypes (LDHA and LDHB) in the HR group (Figure 2B). Twelve of the differentiated proteins were mapped into a network wherein key regulators were focused (Figure 2C). Within them, pro-inflammatory cytokine IL-6 has been widely recognized as a risk factor for COVID-19 [19, 20] and clinically observed to be positively correlated with serum LDH levels [21]. IL-6 can activate cellular tumor antigen p53 (TP53), which facilitates cell apoptosis and could enhance LDHA expression in blood. This network also includes CCAAT/enhancer-binding protein beta (CEBPB) which mediates immune and inflammatory responses [22], and sterol regulatory element binding transcription factor 1 (SREBF1) which regulates lipid metabolisms that has been reported dysregulated in severe COVID-19 patients [15]. Taken together, the proteomic difference between LR and HR patients reflected different host responses between the non-severe and severe COVID-19 patients.

Of the 34 differentially expressed metabolites listed in Supplementary Fig. 2A, 88.2% (30/34) were upregulated, and 52.9% (18/34) were lipids. Within them, 7-hydroxycholesterol (beta) mediates oxidative stress and induces cell apoptosis. It was elevated during hepatitis B virus (HBV) and hepatitis C virus (HCV) infections [23] (Fig 2A and Fig 2B, lower panel). The protein-metabolite joint network generated using IPA (Supplementary Fig. 2B) proposed two upstream molecules to regulate LDHA expression, including hypoxia-inducible factor 1 (HIF1) that mediates hypoxic and inflammatory microenvironments [24] and fibronectin 1 (FN1) that involves COVID-19 lung fibrosis [25]. The dysregulated metabolites further

245 consolidate disturbed host responses in association with serum LDH increase
246 uncovered by the proteomic data.
247

Protein and metabolite change in patients with exceptionally high serum LDH
Next, we narrowed our focus to the two patients with exceptionally high serum
LDH levels on admission (HR3 and HR7, HR outliers), and compared their proteomic
patterns with the other HR patients (Figure 3A). 38 proteins including LDHA and
LDHB were differentially expressed ($p < 0.05$, Figure 3A). Metascape pathway
enrichment nominated 23 proteins associated with immune system process
(GO:0002376, $p < 0.001$) and 21 proteins associated with metabolic process
(GO:0008152, $p < 0.001$) (Supplementary Fig 3B). The top enriched immune-related
pathways are the activation of immune response (GO:0002253, $p < 0.001$) and
humoral immunity response (GO:0006959, $p < 0.001$), while the top enriched
metabolic pathway relates to cofactors (R-HSA-89 78934, $p < 0.001$) (Supplementary
Fig. 3A). IPA analysis detailed the top metabolic functions as protein ubiquitination
pathway and pyruvate fermentation to lactate (Supplementary Fig 3C). Especially, the
HIF1α signaling pathway showed a drastic activation in the HR (outliers) group. As
for characteristic proteins in HR (outliers), our data uncovered a dysregulated protein
group which includes five up-regulated proteasome subunits, namely PSMA3,
PSMA4, PSMA5, PSMB1, and PSMB3 (Figure 3B), possibly due to cell apoptosis
[26] from organ/tissue damage. They are the mediators of protein ubiquitination and
associate with NF-κB signaling (GO:0038061, $p < 0.001$). Six of the seven
differentially expressed immunoglobulin residues (IGHV3-43, IGHV3-30-5,
IGKV1-5, IGLV1-36, IGKV1-17, and IGKV2-24) (Supplementary Fig. 4A) were
up-regulated in HR (outliers), suggesting that humoral immunity at the point of
detection was suppressed or not activated. For the other up-regulated proteins in HR
(outliers) (Figure 3B), CES1 is a hepatic protein and its release in blood suggests liver
injuries. Protein disulfide-isomerase (P4HB) was reported to up-rise in response to
hypoxia [27]. GAPDH could enhance HIF activity [28] via NF-κB induction activated
in hypoxia [29], which contributes to heat shock protein 90-alpha (HSP90AA1)
upregulation [30] to form protein complexes with Hif1α. Dipeptidyl peptidase 4
(DPP4), also known as CD26, is a downstream factor to mark HIF pathway induction
[31]. Especially, the down-regulated protein in HR (outliers) includes CPB2 as a basic
carboxypeptidase that suppresses complement system-mediated inflammation [32]. Its
deficiency could lead to accelerated acute lung injuries [33]. 84.6% (11/13) of the
dysregulated metabolites were lipids (Supplementary Fig. 4B), suggesting disturbed
lipid metabolism accompanied with serum LDH changes. The network analysis
(Supplementary Fig. 4C) further proposed LDH elevation to be associated with
HSP90AA1 and proteasomes.
284

Serum LDH elevation might be driven by tissue injuries and hypoxia
Taking together all the perturbed molecules as highlighted above (Figure 2B and
3B), we propose a putative working model for the serum LDH elevation in
COVID-19 patients (Figure 3C). On the one hand, the inflammation processes
triggered by the host immune system induce apoptosis of the infected cells, leading to
the release of intracellular LDH into the blood. In high-risk cases, these immune
activities result in over-reactive inflammation processes (like "cytokine storm") [34],
thereby releasing higher levels of serum LDH from multiple organs/tissues [10]. On
the other hand, oxygen homeostasis was disturbed in severe COVID-19 patients [12].

Hypoxia reactions occur to accumulate lactate via glycolysis. LDH can balance lactate
secretion via pyruvate fermentation and a series of metabolic regulation
(Supplementary Fig. 3A and 3C) to maintain cellular homeostasis [35]. The activated
NF-κB and HIF pathways in hypoxia conditions could also induce inflammatory
responses [36].
299
300

CONCLUDING REMARKS

Here we systematically investigated serum LDH elevation in COVID-19 patients.
We thoroughly inspected both clinical and molecular profiles of 144 COVID-19
patients. We confirmed serum LDH as the best independent risk indicator, and further
optimized a threshold of 247 U/L for stratifying COVID-19 patients based on the
serum LDH level. Our data showed that the serum LDH declined thereafter, patients
with serum LDH levels higher than the threshold on admission are prone to severe
conditions, hence determined as high-risk (HR) patients, and those lower than the
threshold as low-risk (LR) patients.

Proteomic differences between LR and HR groups exposed a list of dysregulated
host responses. Among them, acute inflammatory responses, platelet degranulation
and complement cascade have been reported in previous studies comparing severe and
non-severe COVID-19 patients [15, 37]. Blood coagulation has been highlighted in
another report that compares COVID-19 patients with high and low IL-6 levels [38].
Immune behaviors including activation of immune response and humoral immune
response were further enriched during the intra-comparison within HR patients,
suggesting that the immune behaviors are closely related to serum LDH expression.
Proteomic profiling also highlighted a list of hypoxia related proteins and functions,
including P4HB, DPP4, GAPDH, HSP90AA1, NF-κB and HIF signaling, suggesting
that hypoxia might have contributed to elevated LDH. The metabolomic profiling
complements findings on the proteomic level and further emphasizes dysregulated
lipid metabolism. Taken together, we propose that elevation of serum LDH might
attribute to inflammation-related tissue injuries and hypoxia-related metabolism.

This study is limited by several factors. Firstly, the single-center study with a
relatively small patient cohort is subject to experimental bias. Moreover, proteome
data from only 14 individuals were acquired, from which only 2 patients were
determined as high-risk group outliers for comparative analysis. It is worth noting that
serum LDH elevation is not specific to COVID-19 disease [39]. Further studies
should conduct clinical validation on larger cohorts, and compare the molecular
differences including control patients with other diseases with similar symptoms.
331

CONFLICT OF INTERESTS

The research group of T.G. is partly supported by Tencent, Thermo Fisher Scientific,
SCIEX, and Pressure Biosciences Inc. T.G. is a shareholder of Westlake Omics Inc.
G.R. is an employee of Westlake Omics Inc.

ACKNOWLEDGMENTS

This work was supported by grants from National Key R&D Program of China (No.
2020YFE0202200), National Natural Science Foundation of China (81972492,

21904107, 81672086, 82072333), Zhejiang Provincial Natural Science Foundation for
Distinguished Young Scholars (LR19C050001), Hangzhou Agriculture and Society
Advancement Program (20190101A04), Zhejiang Provincial Natural Science
Foundation of China (LQ19H100001). And Westlake Education Foundation, Tencent
Foundation. We thank Westlake University Supercomputer Center for assistance in
data storage and computation.

References

[1] Huang, C., Wang, Y., Li, X., Ren, L., *et al.*, Clinical features of patients infected with 2019

novel coronavirus in Wuhan, China. *Lancet* 2020, *395*, 497-506.

[2] Chen, N., Zhou, M., Dong, X., Qu, J., *et al.*, Epidemiological and clinical characteristics of

99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*

2020, *395*, 507-513.

[3] Hui, D. S.-C., Wong, P.-C., Wang, C., SARS: clinical features and diagnosis. *Respirology*

(Carlton, Vic.) 2003, *8 Suppl*, S20-S24.

[4] Huang, E.-J., Kuo, W.-W., Chen, Y.-J., Chen, T.-H., *et al.*, Homocysteine and other

biochemical parameters in Type 2 diabetes mellitus with different diabetic duration or diabetic

retinopathy. *Clinica Chimica Acta* 2006, *366*, 293-298.

[5] Ding, J., Karp, J. E., Emadi, A., Elevated lactate dehydrogenase (LDH) can be a marker of

immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and

their microenvironments. *Cancer Biomark* 2017, *19*, 353-363.

[6] Wan, S., Xiang, Y., Fang, W., Zheng, Y., *et al.*, Clinical features and treatment of COVID-19

patients in northeast Chongqing. *J Med Virol* 2020, *92*, 797-806.

[7] Yuan, J., Zou, R., Zeng, L., Kou, S., *et al.*, The correlation between viral clearance and

biochemical outcomes of 94 COVID-19 infected discharged patients. *Inflamm Res* 2020, *69*,

599-606.

[8] Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., *et al.*, Discovery of a novel coronavirus

associated with the recent pneumonia outbreak in humans and its potential bat origin. *bioRxiv*

2020.

[9] Chen, G., Wu, D., Guo, W., Cao, Y., *et al.*, Clinical and immunological features of severe

and moderate coronavirus disease 2019. *J Clin Invest* 2020, *130*, 2620-2629.

[10] Shi, J., Li, Y., Zhou, X., Zhang, Q., *et al.*, Lactate dehydrogenase and susceptibility to

deterioration of mild COVID-19 patients: a multicenter nested case-control study. *BMC Med*

2020, *18*, 168-168.

[11] Poggiali, E., Zaino, D., Immovilli, P., Rovero, L., *et al.*, Lactate dehydrogenase and

C-reactive protein as predictors of respiratory failure in CoVID-19 patients. *Clin Chim Acta*

2020, *509*, 135-138.

[12] Han, Y., Zhang, H., Mu, S., Wei, W., *et al.*, Lactate dehydrogenase, an independent risk

factor of severe COVID-19 patients: a retrospective and observational study. *Aging (Albany*

NY) 2020, *12*, 11245-11258.

[13] Henry, B. M., Aggarwal, G., Wong, J., Benoit, S., *et al.*, Lactate dehydrogenase levels

predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. *The*

American Journal of Emergency Medicine 2020, *38*, 1722-1726.

[14] National Health Commission 2020.

[15] Shen, B., Yi, X., Sun, Y., Bi, X., *et al.*, Proteomic and Metabolomic Characterization of

COVID-19 Patient Sera. *Cell* 2020, *182*, 59-72.e15.

[16] Zheng, Z., Peng, F., Xu, B., Zhao, J., *et al.*, Risk factors of critical & mortal COVID-19
cases: A systematic literature review and meta-analysis. *J Infect* 2020, *81*, e16-e25.
[17] Zou, X., Fang, M., Li, S., Wu, L., *et al.*, Characteristics of Liver Function in Patients With
SARS-CoV-2 and Chronic HBV Coinfection. *Clin Gastroenterol Hepatol* 2020.
[18] Zhou, Y., Zhou, B., Pache, L., Chang, M., *et al.*, Metascape provides a biologist-oriented
resource for the analysis of systems-level datasets. *Nat Commun* 2019, *10*, 1523.
[19] D'Alessandro, A., Thomas, T., Dzieciatkowska, M., Hill, R. C., *et al.*, Serum Proteomics in
COVID-19 Patients: Altered Coagulation and Complement Status as a Function of IL-6 Level.
Journal of Proteome Research 2020, *19*, 4417-4427.
[20] Tian, J., Yuan, X., Xiao, J., Zhong, Q., *et al.*, Clinical characteristics and risk factors
associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a
multicentre, retrospective, cohort study. *Lancet Oncol* 2020, *21*, 893-903.
[21] Liu, T., Zhang, J., Yang, Y., Ma, H., *et al.*, The role of interleukin-6 in monitoring severe
case of coronavirus disease 2019. *EMBO Mol Med* 2020, *12*, e12421-e12421.
[22] Kinoshita, S., Akira, S., Kishimoto, T., A member of the C/EBP family, NF-IL6 beta, forms
a heterodimer and transcriptionally synergizes with NF-IL6. *Proc Natl Acad Sci U S A* 1992, *89*,
1473-1476.
[23] Yoshida, Y., Kodai, S., Takemura, S., Minamiyama, Y., Niki, E., Simultaneous
measurement of F2-isoprostane, hydroxyoctadecadienoic acid, hydroxyeicosatetraenoic acid,
and hydroxycholesterols from physiological samples. *Anal Biochem* 2008, *379*, 105-115.
[24] Jahani, M., Dokaneheifard, S., Mansouri, K., Hypoxia: A key feature of COVID-19
launching activation of HIF-1 and cytokine storm. *J Inflamm (Lond)* 2020, *17*, 33-33.
[25] Xu, J., Xu, X., Jiang, L., Dua, K., *et al.*, SARS-CoV-2 induces transcriptional signatures in
human lung epithelial cells that promote lung fibrosis. *Respir Res* 2020, *21*, 182.
[26] Weathington, N. M., Mallampalli, R. K., New insights on the function of SCF ubiquitin E3
ligases in the lung. *Cellular signalling* 2013, *25*, 1792-1798.
[27] Ko, H. S., Uehara, T., Nomura, Y., Role of ubiquilin associated with protein-disulfide
isomerase in the endoplasmic reticulum in stress-induced apoptotic cell death. *The Journal of*
biological chemistry 2002, *277*, 35386-35392.
[28] Chiche, J., Pommier, S., Beneteau, M., Mondragon, L., *et al.*, GAPDH enhances the
aggressiveness and the vascularization of non-Hodgkin's B lymphomas via
NF-kappaB-dependent induction of HIF-1alpha. *Leukemia* 2015, *29*, 1163-1176.
[29] Li, Y., Yang, L., Dong, L., Yang, Z. W., *et al.*, Crosstalk between the Akt/mTORC1 and
NF-kappaB signaling pathways promotes hypoxia-induced pulmonary hypertension by
increasing DPP4 expression in PASMCs. *Acta pharmacologica Sinica* 2019, *40*, 1322-1333.
[30] Zuehlke, A. D., Beebe, K., Neckers, L., Prince, T., Regulation and function of the human
HSP90AA1 gene. *Gene* 2015, *570*, 8-16.

[31] Dang, D. T., Chun, S. Y., Burkitt, K., Abe, M., *et al.*, Hypoxia-inducible factor-1 target
genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.
Cancer research 2008, *68*, 1872-1880.
[32] Leung, L. L. K., Morser, J., Carboxypeptidase B2 and carboxypeptidase N in the crosstalk
between coagulation, thrombosis, inflammation, and innate immunity. *Journal of thrombosis*
and haemostasis : JTH 2018.
[33] Naito, M., Taguchi, O., Kobayashi, T., Takagi, T., *et al.*, Thrombin-activatable fibrinolysis
inhibitor protects against acute lung injury by inhibiting the complement system. *American*
journal of respiratory cell and molecular biology 2013, *49*, 646-653.
[34] Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., *et al.*, COVID-19: consider cytokine
storm syndromes and immunosuppression. *Lancet* 2020, *395*, 1033-1034.
[35] Lee, D. C., Sohn, H. A., Park, Z. Y., Oh, S., *et al.*, A lactate-induced response to hypoxia.
Cell 2015, *161*, 595-609.
[36] D'Ignazio, L., Bandarra, D., Rocha, S., NF-kappaB and HIF crosstalk in immune
responses. *The FEBS journal* 2016, *283*, 413-424.
[37] Messner, C. B., Demichev, V., Wendisch, D., Michalick, L., *et al.*, Ultra-High-Throughput
Clinical Proteomics Reveals Classifiers of COVID-19 Infection. *Cell Systems* 2020, *11*,
11-24.e14.
[38] D'Alessandro, A., Thomas, T., Dzieciatkowska, M., Hill, R. C., *et al.*, Serum Proteomics in
COVID-19 Patients: Altered Coagulation and Complement Status as a Function of IL-6 Level.
Journal of Proteome Research 2020.
[39] Hui, D. S., Wong, P. C., Wang, C., SARS: clinical features and diagnosis. *Respirology*
2003, *8 Suppl*, S20-24.
444

Table 1 Clinical characteristics and Laboratorial indexes of COVID-19 patients.

Characteristics	Total (N=144)	Non-severe (N=108)	Severe (N=36)	p value
Age, years median (IQR)	47 (38-56)	45 (37-54)	55 (48-65)	0.000
Sex, Male	77 (53.5)	57 (52.8)	20(55.6)	0.772
Symptoms on Admission				
Fever, %	98 (68.1)	66 (61.1)	32 (88.9)	0.002
Pharyngalgia, %	17 (11.8)	15 (13.9)	2 (5.6)	0.180
Cough, %	65 (45.1)	47 (43.5)	18 (50.0)	0.499
Expectoration, %	26 (18.1)	19 (17.6)	7 (19.4)	0.802
Tiredness, %	16 (11.1)	10 (9.3)	6 (16.7)	0.221
Headache, %	16 (11.1)	9 (8.3)	7 (19.4)	0.066
Medical Treatment				
Oxygen inhalation, %	97 (67.4)	63 (58.3)	34 (94.4)	0.000
Antibiotics, %	26 (18.1)	15 (13.9)	11 (30.6)	0.024
Antivirus, %	144 (100)	108 (100)	36 (100)	1.000
Glucocorticoid, %	37 (25.7)	13 (12.0)	24 (66.7)	0.000
Gamma Immunoglobulin, %	33 (22.9)	7 (6.5)	26 (72.2)	0.000
Laboratorial Indexes				
LDH (ULN) [a]				0.000
Low or normal	114 (79.2)	99 (91.7)	15 (41.7)	
High	30 (20.8)	9 (8.3)	21 (58.3)	
ALT (ULN) [b]				0.041
Low or normal	129 (89.6)	100 (92.6)	29 (80.6)	
High	15 (10.4)	8 (7.4)	7 (19.4)	
AST (ULN) [c]				0.000
Low or normal	124 (86.1)	100 (92.6)	24 (66.7)	
High	20 (13.9)	8 (7.4)	12 (33.3)	
Total bilirubin (ULN) [d]				0.340
Low or normal	122(84.7)	93(86.1)	29 (80.6)	
High	22 (15.3)	15 (13.9)	7 (19.4)	
Total protein (LLN) [e]				0.331
High or normal	116 (80.6)	89 (82.4)	27 (75.0)	
Low	28 (19.4)	19 (17.6)	9 (25.0)	
Urea (ULN) [f]				0.004
Low or normal	138 (95.8)	107 (99.1)	31 (86.1)	
High	6 (4.2)	1 (0.9)	5 (13.9)	
Creatinine (ULN) [g]				0.014
Low or normal	139 (96.5)	107 (99.1)	32 (88.9)	
High	5 (3.5)	1 (0.9)	4 (11.1)	
Creatine kinase (ULN) [h]				0.000
Low or normal	123 (85.4)	99 (91.7)	24 (66.7)	
High	21 (14.6)	9 (8.3)	12 (33.3)	

Abbreviations: LDH, Lactate dehydrogenase; AST, aspartate aminotransferase; ALT, Alanine

aminotransferase.

[a] ULN of LDH for male and female are 285 and 227 U/L, respectively.

[b] ULN of ALT for male and female are 50 and 40 U/L, respectively.

[c] ULN of AST for male and female are 40 and 35 U/L, respectively.

[d] ULN of total bilirubin is 20.5 μmol/L.

[e] LLN of total protein is 65 g/L.

[f] ULN of urea for male and female are 8 and 8.8 U/L, respectively.

[g] ULN of creatinine for male and female are 104 and 84 μmol/L, respectively.

[h] ULN of CK for male and female are 172 and 140 U/L, respectively.

Abbreviations: ULN, upper limit of normal; LLN, lower limit of normal; LDH, Lactate dehydrogenase;
AST, aspartate aminotransferase; ALT, Alanine aminotransferase.

Table 2 Medical records of temporal change associated severe patients.

Patient Num.	HR1	HR2	HR3	HR4	HR5	HR6	HR7	LR1	LR2	LR3	LR4	LR5	LR6	LR7
Sex	F	M	F	M	M	M	M	M	F	M	F	M	M	M
Age	>60	>60	>60	≤60	≤60	≤60	≤60	>60	≤60	>60	≤60	≤60	≤60	≤60
Days for Admission	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Days for Progression to Severe Stage	2	1	4	0*	1	1	3							
Days for Proteomic Sampling	5	2	2	2	2	1	1	2	6	4	5	4	11	1
Days for Metabolomic Sampling	8	2	2	11	3	1	1	2	1	3	1	1	1	1
Basic Diseases	Left breast tumor resection	Benign thyroid tumor resection		Hypertension, gout arthritis, hyperuricemia, chronic renal insufficiency for 14 years	High blood pressure, type 2 diabetes	Chronic viral hepatitis b more than 20 years, hypothyroidism 5 years	Hepatitis b virus infection more than 10 years ago.	Type 2 diabetes, hyperlipidemia						Hepatitis b virus infection 20 years, type 2 diabetes

459   *: Patient HR4 was diagnosed as severe before admission to Taizhou Hospital.
460
461

462 **Supplementary Table 1** Dynamic changes of clinical laboratory test results in severe
463 and non-severe COVID-19 patients

Characteristics	Total COVID-19 patients (n=144)	
	Severe (n=36)	non-Severe (n=108)
LDH, U/L		
1-7 day	265.0 (229.5-312.3)	183.0 (161.0-214.5)
8-14 day	221.0 (183.0-249.0)	160.0 (137.0-181.0)
15-21 day	196.0 (176.5-211.0)	156.0 (131.3-182.0)
>21 day	173.0 (143.5-199.0)	147.5 (138.0-162.3)
Total bilirubin, μmol/L		
1-7 day	12.2 (7.8-17.6)	12.3 (8.3-17.2)
8-14 day	14.2 (10.6-23.0)	14.5 (11.4-17.0)
15-21 day	13.1 (7.9-18.0)	11.8 (8.7-14.7)
>21 day	9.9 (6.5-13.0)	7.5 (6.5-11.6)
Urea, μmol/L		
1-7 day	4.3 (3.5-5.7)	3.9 (3.2-5.1)
8-14 day	6.0 (4.5-7.8)	3.6 (3.0-4.2)
15-21 day	4.6 (3.6-6.1)	3.7 (3.1-4.3)
>21 day	4.1 (3.6-4.1)	3.8 (3.0-4.5)
Total protein, g/L		
1-7 day	68.7 (64.2-72.4)	69.2 (66.0-74.0)
8-14 day	70.6 (65.9-75.3)	67.0 (63.0-69.9)
15-21 day	65.7 (60.7-71.2)	65.9 (64.3-70.5)
>21 day	62.9 (58.2-67.0)	68.9 (65.8-70.7)
AST, U/L		
1-7 day	30.0 (25.3-50.0)	22.0 (19.0-28.0)
8-14 day	23.5 (19.0-31.3)	22.0 (17.0-26.0)
15-21 day	24.0 (18.0-36.5)	21.0 (19.0-25.0)
>21 day	22.0 (20.0-41.5)	22.0 (20.0-26.0)
ALT, U/L		
1-7 day	30.0 (19.0-39.0)	19.0 (13.0-30.0)
8-14 day	35.5 (23.0-52.8)	20.0 (15.0-34.0)
15-21 day	36.5 (20.8-55.5)	23.0 (17.0-36.3)
>21 day	27.0 (20.0-41.0)	26.5 (19.5-35.5)
Creatine kinase, U/L		
1-7 day	104.5 (67.5-209.3)	55.5 (38.5-79.8)
8-14 day	31.0 (26.0-41.0)	35.0 (27.0-50.0)
15-21 day	28.0 (22.0-39.0)	43.0 (29.0-55.0)
>21 day	26.0 (19.0-32.8)	43.0 (32.0-56.0)
Creatinine, μmol/L		
1-7 day	75.5 (66.0-93.0)	71.5 (62.5-84.0)

8-14 day	75.0 (65.0-91.0)	76.0 (63.0-85.0)
15-21 day	69.5 (60.5-92.8)	71.0 (62.0-81.0)
>21 day	67.0 (57.5-87.0)	72.0 (62.0-79.3)

464 **Supplementary Table 2** Cox regression model for univariate and multivariate
465 analysis.

Characteristics	Cohort 1 (n=115)				Cohort 2 (n=29)	
	Univariate analysis		Multivariate analysis		Univariate analysis	
	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
Age						
<60	1	0.024	1	0.302		
≥60	2.635 (1.135-6.117)		1.604 (0.654-3.931)			
Sex						
Male	1	0.661				
Female	0.836 (0.375-1.861)					
Fever						
No	1	0.028	1	0.083		
Yes	3.862 (1.155-12.912)		3.042 (0.865-10.697)			
Coexisting disorders						
No	1	0.162				
Yes	1.753 (0.799-3.848)					
LDH (ULN) [a]						
Low or normal	1	0	1	0	1	0.037
High	10.228 (4.550-22.993)		6.263 (2.377-16.502)		3.559 (1.077-11.766)	
ALT (ULN) [b]						
Low or normal	1	0.063				
High	2.534 (0.949-6.765)					
AST (ULN) [c]						
Low or normal	1	0	1	0.468		
High	5.030 (2.212-11.440)		1.464 (0.522-4.103)			
Total bilirubin (ULN) [d]						
Low or normal	1	0.106				
High	2.136 (0.852-5.357)					
Total protein (LLN) [e]						

High or normal	1	0.835			
Lower	0.892 (0.304-2.612)				
Urea (ULN) [f]					
Low or normal	1	0.012	1	0.086	
High	4.724 (1.405-15.880)		5.517 (0.786-38.722)		
Creatinine (ULN) [g]					
Low or normal	1	0.024	1	0.264	
High	4.017 (1.198-13.464)		0.314 (0.041-2.400)		
Creatine kinase (ULN) [h]					
Low or normal	1	0.000	1	0.171	
High	5.510 (2.475-12.266)		1.952 (0.749-5.090)		

 Figure Legends

Figure 1 Serum LDH expression levels in the study cohort. A) Serum LDH
expression levels in different time courses grouped by age. B) Serum LDH expression
levels in different time courses grouped by sex. C) Serum LDH expression levels of
severe and non-severe patients during the admission and discharge stage. D) Serum
LDH expression levels of severe and non-severe patients in time courses at the 3-day
interval. E) Receiver operating characteristic (ROC) of the study cohort when setting
LDH expression level cutoff as 247 U/L. F) Individual inspection of 14 patients' LDH
expression dynamics. Yellow dash line, Patient HR1; Purple dash line, Patient LR4.
477

480 **Figure 2 Molecular differences between low- and high-risk patients.** A) Heatmap
481 of 34 differentially expressed proteins and two differentially expressed metabolites.
482 LR, low-risk patients. HR, high-risk patients. B) Boxplots of nine selected
483 differentially expressed proteins and two selected differentially expressed metabolites.
484 C) Protein network including 12 selected differentially expressed proteins.

485
486

Figure 3 Molecular differences between HR (basic) and HR (outliers) patients. A) Heatmap of 38 differentially expressed proteins. LR, low-risk patients. HR, high-risk patients. B) Boxplots of 13 selected differentially expressed proteins. C) Proposed mechanism for serum LDH elevation in COVID-19 patients.

499   **Supplementary Figure Legends**

500   **Supplementary Fig 1. Pathway analyses of differentially expressed proteins**
501   **between LR and HR patients.** A) Heatmap of Gene Ontology pathway enrichment
502   using Metascape. B) Heatmap of Coronascape enrichment using Metascape. C)
503   Barplot of Pathway enrichment using IPA.

504
505

506 **Supplementary Fig 2. Extended analyses of differentially expressed molecules**
507 **between LR and HR patients.** A) Heatmap of differentially expressed metabolites. B)
508 Protein-metabolic joint network analyses of differentially expressed molecules.

509
510

511 **Supplementary Fig 3. Pathway analyses of differentially expressed proteins**
512 **between HR (Basic) and HR (Outliers) patients.** A) Heatmap of Gene Ontology
513 pathway enrichment using Metascape. B) Heatmap of Gene Ontology (parent)
514 pathway enrichment using Metascape. C) Barplot of Pathway enrichment using IPA

515
516   .
517
518

519 **Supplementary Fig 4. Extended analyses of differentially expressed molecules**
520 **between HR (Basic) and HR (Outliers) patients.** A) Heatmap of differentially
521 expressed metabolites. B) Protein-metabolic joint network analyses of differentially
522 expressed molecules.